eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
Designation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a...